Retrovir AZT: The 16-company Inter-Company Collaboration for AIDS Drug Development and Parexel International Corp. started a study of two different three-drug r

The goal of the trial is to reduce viral load and increase CD4 counts in patients with starting CD4 counts of 200-500. The study will compare the combination of Glaxo Wellcome's Retrovir, Bristol-Myers' Videx and BCHXF's 3TC to the use of Retrovir, Videx and Boehringer Ingelheim's nevirapine. Both triple combinations will be compared to the two-drug regimen of Retrovir and Videx. ...